person · Reporting owner
Sutherland Everett Rand
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allakos Inc.ALLK · Entity 79644 | Director | August 01, 2023 | August 03, 2023 |
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | September 14, 2026 | September 17, 2026 |
| Translate Bio, Inc.TBIO · Entity 135439 | President | September 14, 2021 | September 14, 2021 |
| Upstream Bio, Inc.UPB · Entity 5743 | Director · Chief Executive Officer | September 16, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allakos Inc.
Report date August 01, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.55 · Expires 2033-08-01 | Direct | 154,786 |
Reported balance
After 2023-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-01 · Grant · Acquired 154,786 · Balance 154,786 F1: The option vests as to one thirty-sixth (1/36) of the shares monthly over a three year period, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to one thirty-sixth (1/36) of the shares monthly over a three year period, subject to the Reporting Person continuing as a service provider through each such date.
Krystal Biotech, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13 | Direct | 1,187 |
Reported balance
After 2026-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 471 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.37 · Expires 2031-03-22 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 300,000 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2: This option was granted on March 22, 2021. This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F2: This option was granted on March 22, 2021. This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025.
Upstream Bio, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,717 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 2,095 · Balance 68,717 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:05 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 2,095 | $5.49 | $11,501.55 |
DisclosureSEC source: 0001193125-26-394325 · ownership.xml · nonDerivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,717 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001852880-26-000002 · wk-form4_1789603389.xml · derivative · entry 2 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $340.03 | $0.00 |
DisclosureSEC source: 0001852880-26-000002 · wk-form4_1789603389.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:05 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 2,095 | $6.10 | $12,779.50 |
DisclosureSEC source: 0001193125-26-274125 · ownership.xml · nonDerivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,812 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:00 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 2,093 | $9.29 | $19,443.97 |
DisclosureSEC source: 0001193125-26-111124 · ownership.xml · nonDerivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,907 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:15 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001193125-26-004754 · ownership.xml · derivative · entry 2 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:15 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004754 · ownership.xml · nonDerivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:18 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $137.46 | $0.00 |
DisclosureSEC source: 0001852880-25-000003 · wk-form4_1751321917.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 22:32 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000950170-25-016471 · ownership.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 23:24 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $183.64 | $0.00 |
DisclosureSEC source: 0001852880-24-000002 · wk-form4_1719876240.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 22:02 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 154,786 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001209191-23-044533 · doc4.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,786 Underlying: Common Stock · 154,786 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option vests as to one thirty-sixth (1/36) of the shares monthly over a three year period, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:31 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001711279-23-000057 · wk-form4_1688416274.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:18 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001711279-22-000042 · wf-form4_165670668078150.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period. Read SEC document |
| January 31, 2022 Filed Jan 31, 2022 21:47 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 13,600 | $0.00 Strike: $59.00 | $0.00 |
DisclosureSEC source: 0001852880-22-000002 · wf-form4_164366560575664.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-01-31 F1 · derivative.exercise_date: The options were awarded on January 31, 2022 and vest in equal monthly tranches over a three-year period. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:34 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001209191-21-056067 · doc4.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2031-03-22 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2 · derivative.exercise_date: This option was granted on March 22, 2021. This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 20:40 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001209191-21-022573 · doc4.xml · derivative · entry 1 Sutherland Everett Rand · CIK 0001852880 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-03-22 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.